A Phase 3 interventional study of Ocrelizumab and Ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, sponsored by Genentech, Inc.. Completed at 82 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-05-26.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 3, and was the 2nd registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:
Celltrion · Sites in Poland
Ages 18–55
University of California, San Francisco · Sites in United States
Ages 18–65
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2016.
This study's enrollment of 608 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 404 across the 10 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche: 2 open now, 5 under way, 2 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2016, is one of 6 in phase 3, and was the 6th registered.
Hoffmann-La Roche’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2004.
3 of the studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05906992Phase 3CelltrionA Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | 2027-02 |
| NCT05296161Amsterdam UMC, location VUmcB Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis | 2027-02 |
| NCT06495593University of California, San FranciscoEffects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 14 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT. Participants will receive ocrelizumab as an initial dose of two 300-milligrams (mg) intravenous (IV) infusions (600 mg total) separated by 14 days followed by one 600-mg IV infusion for a maximum of 4 doses (up to 96 weeks). Anticipated time on study treatment is 96 weeks.
Participants who complete their Week 72 ocrelizumab infusion and do not experience any serious infusion related reaction (IRR) throughout the main study will be eligible to enroll in an optional, open-label, non-randomized substudy to MN30035 and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. This substudy will enroll approximately 100 patients from MN30035 main study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
Drug: Ocrelizumab
Participants with no serious IRR throughout the main study will be eligible to enroll in an optional substudy and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. Ocrelizumab will be administered IV as a single 600-mg dose at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
Drug: Ocrelizumab
Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
Also known as: RO4964913
Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
Also known as: RO4964913
Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period
Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 gadolinium (Gd)-enhanced lesion on brain magnetic resonance imaging (MRI) or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.
Time frame: Baseline up to Week 96
Percentage of Participants With Infusion Related Reactions (IRRs) in Optional Substudy
Rate and frequency of Grade 3 or 4 IRRs with onset on or after the shorter ocrelizumab infusion
Time frame: Week 96 to Week 100
Percentage of Participants Without Any Protocol-Defined Events During 24-Week and 48-Week Period
Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 Gd-enhanced lesion on brain MRI or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.
Time frame: Baseline up to Weeks 24 and 48
Time to Protocol-Defined Event
Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 Gd-enhanced lesion on brain MRI or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.
Time frame: Baseline up to Week 96
Total Number of Protocol-Defined Relapses Per Participant Year During 96-week Period
Protocol-defined relapse is an occurrence of new or worsening neurological symptoms attributable to multiple sclerosis which must persist for greater than (\>) 24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) and immediately preceded by a stable or improving neurological state for least 30 days. The Adjusted Annualized Relapse Rate was adjusted by baseline Expanded Disability Status Scale (EDSS \<2.5 vs. \>=2.5) and number of previous disease-modifying treatments (DMTs =1 vs. \>1)
Time frame: Baseline up to Week 96
Time to Onset of First Protocol-Defined Relapse
Protocol-defined relapse is an occurrence of new or worsening neurological symptoms attributable to multiple sclerosis which must persist for \>24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) and immediately preceded by a stable or improving neurological state for least 30 days.
Time frame: Baseline up to Week 96
Time to Onset of First T1 Gd-Enhanced Lesion as Detected by Brain MRI
Time frame: Baseline up to Week 96
Time to Onset of First New and/or Enlarging T2 Lesion as Detected by Brain MRI
Time frame: Baseline up to Week 96
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks According to Expanded Disability Status Scale (EDSS) Score
Time frame: Baseline up to Week 96
Total Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI
The analyses included participants who had an interpretable MRI at the time point of interest. Participants having 0, 1, 2, 3, and greater than 3 lesions at weeks 24, 48, and 96 were included in the analysis.
Time frame: Weeks 24, 48, and 96
Change From Baseline in Total T2 Lesion Volume as Detected by Brain MRI
Baseline data is represented as mean; post-Baseline date are represented as mean changes.
Time frame: Baseline, Weeks 24, 48, and 96
Total Number of New and/or Enlarging T2 Lesions as Detected by Brain MRI
Time frame: Weeks 24, 48, and 96
Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline up to 100 weeks
The study was conducted in North America at 90 study sites in the U.S. and Canada.
| Milestone | Ocrelizumab | Ocrelizumab (Substudy) |
|---|---|---|
| Started | 608 | 0 |
| Completed | 389 | 0 |
| Not completed | 219 | 0 |
| Withdrew: Adverse event | 9 | 0 |
| Withdrew: Lost to follow-up | 5 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Pregnancy | 7 | 0 |
| Withdrew: Withdrawal by subject | 20 | 0 |
| Withdrew: Protocol deviation | 2 | 0 |
| Withdrew: Continued on commercial ocrevus | 164 | 0 |
| Withdrew: Failed drug test | 1 | 0 |
| Withdrew: Incarceration | 1 | 0 |
| Withdrew: Pregnancy attempts | 2 | 0 |
| Withdrew: Site closing | 6 | 0 |
| Milestone | Ocrelizumab | Ocrelizumab (Substudy) |
|---|---|---|
| Started | 0 | 129 |
| Completed | 0 | 125 |
| Not completed | 0 | 4 |
| Withdrew: Non-safety reason (moved out of state) | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 |
Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 gadolinium (Gd)-enhanced lesion on brain magnetic resonance imaging (MRI) or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period | 48.1 (43.9 to 52.3) |
Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 Gd-enhanced lesion on brain MRI or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Week 24 | 59.0 (54.9 to 63.1) |
| Week 48 | 51.2 (47.0 to 55.4) |
Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 Gd-enhanced lesion on brain MRI or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.
| Weeks | Ocrelizumab |
|---|---|
| Time to Protocol-Defined Event | NA (53.86 to NA) |
Protocol-defined relapse is an occurrence of new or worsening neurological symptoms attributable to multiple sclerosis which must persist for greater than (\>) 24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) and immediately preceded by a stable or improving neurological state for least 30 days. The Adjusted Annualized Relapse Rate was adjusted by baseline Expanded Disability Status Scale (EDSS \<2.5 vs. \>=2.5) and number of previous disease-modifying treatments (DMTs =1 vs. \>1)
| Number of Relapses/Participant Year | Ocrelizumab |
|---|---|
| Total Number of Protocol-Defined Relapses Per Participant Year During 96-week Period | 0.046 (0.036 to 0.060) |
Protocol-defined relapse is an occurrence of new or worsening neurological symptoms attributable to multiple sclerosis which must persist for \>24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) and immediately preceded by a stable or improving neurological state for least 30 days.
| Weeks | Ocrelizumab |
|---|---|
| Time to Onset of First Protocol-Defined Relapse | NA (NA to NA) |
| Weeks | Ocrelizumab |
|---|---|
| Time to Onset of First T1 Gd-Enhanced Lesion as Detected by Brain MRI | NA (NA to NA) |
| Weeks | Ocrelizumab |
|---|---|
| Time to Onset of First New and/or Enlarging T2 Lesion as Detected by Brain MRI | NA (NA to NA) |
| Weeks | Ocrelizumab |
|---|---|
| Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks According to Expanded Disability Status Scale (EDSS) Score | NA (NA to NA) |
The analyses included participants who had an interpretable MRI at the time point of interest. Participants having 0, 1, 2, 3, and greater than 3 lesions at weeks 24, 48, and 96 were included in the analysis.
| Number of Lesions | Ocrelizumab |
|---|---|
| Week 24 | 33 (0.010 to 0.050) |
| Week 48 | 16 (0.002 to 0.031) |
| Week 96 | 7 (0.002 to 0.026) |
Baseline data is represented as mean; post-Baseline date are represented as mean changes.
| cubic centimeter (cm3) | Ocrelizumab |
|---|---|
| Baseline | 11.551 ± 0.590 |
| Week 24 | -0.484 ± 0.118 |
| Week 48 | -0.549 ± 0.123 |
| Week 96 | -0.560 ± 0.129 |
| Number of Lesions | Ocrelizumab |
|---|---|
| Week 24 | 640 |
| Week 48 | 39 |
| Week 96 | 38 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Percentage of Participants With Adverse Events | 86.3 |
Rate and frequency of Grade 3 or 4 IRRs with onset on or after the shorter ocrelizumab infusion
| Percentage of Participants | Ocrelizumab (Substudy) |
|---|---|
| Percentage of Participants With Infusion Related Reactions (IRRs) in Optional Substudy | 0 (0.0 to 2.8) |
Collected over Baseline up to 100 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocrelizumab | 0/608 (0%) | 47/608 (7.7%) | 406/608 (66.8%) |
| Ocrelizumab (Substudy) | 0/129 (0%) | 2/129 (1.6%) | 16/129 (12.4%) |
| Event | Ocrelizumab | Ocrelizumab (Substudy) |
|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/608 | 1/129 |
| NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/608 | 1/129 |
| AppendicitisInfections and infestations | 3/608 | 0/129 |
| Multiple sclerosis relapseNervous system disorders | 3/608 | 0/129 |
| Suicidal ideationPsychiatric disorders | 3/608 | 0/129 |
| Cholecystitis acuteHepatobiliary disorders | 2/608 | 0/129 |
| PyelonephritisInfections and infestations | 2/608 | 0/129 |
| Urinary tract infectionInfections and infestations | 2/608 | 0/129 |
| EncephalopathyNervous system disorders | 2/608 | 0/129 |
| SeizureNervous system disorders | 2/608 | 0/129 |
| Event | Ocrelizumab | Ocrelizumab (Substudy) |
|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 263/608 | 16/129 |
| Urinary tract infectionInfections and infestations | 88/608 | 0/129 |
| NasopharyngitisInfections and infestations | 64/608 | 0/129 |
| FatigueGeneral disorders | 58/608 | 0/129 |
| Upper respiratory tract infectionInfections and infestations | 57/608 | 0/129 |
| HeadacheNervous system disorders | 56/608 | 0/129 |
| SinusitisInfections and infestations | 37/608 | 0/129 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 36/608 | 0/129 |
| NauseaGastrointestinal disorders | 32/608 | 0/129 |
| Age, Continuous(Years) | Ocrelizumab |
|---|---|
| Mean | 37.2 ± 8.6 |
| Sex: Female, Male(Participants) | Ocrelizumab |
|---|---|
| Female | 438 |
| Male | 170 |
| Race/Ethnicity, Customized(Participants) | Ocrelizumab |
|---|---|
| Hispanic or Latino | 68 |
| Not Hispanic or Latino | 526 |
| Not Stated | 7 |
| Unknown | 7 |
| Race/Ethnicity, Customized(Participants) | Ocrelizumab |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 13 |
| Black or African American | 72 |
| Multiple | 6 |
| Native Hawaiian or other Pacific Islande | 3 |
| Unknown | 17 |
| White | 495 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2016 to primary completion in May 2019, 38 months.
Results were first posted in May 2020, 1 year after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 38 months is close to that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Relapsing-Remitting →